PARIS, November 11, 2016 /PRNewswire/ --
- Toujeo(R) provides a flatter profile than insulin degludec with less within-day fluctuations -
Sanofi [http://www.sanofi.com ] presented today the full results of a pharmacokinetic / pharmacodynamic (PK/PD) study with Toujeo(R) (insulin glargine 300 Units/mL) and insulin degludec 100 Units/mL (Deg-100) at the 16th Annual Diabetes Technology Meeting, Bethesda, Maryland, U.S.
In patients with type 1 diabetes, the Toujeo(R) PK/PD profile at a clinically relevant dose (0.4 U/kg/day, the average dose used in worldwide clinical practice) was flatter and more evenly distributed over 24 hours compared with the profile of insulin degludec. The within-day fluctuation of metabolic activity was 20% lower (p=0.047) for Toujeo(R) than insulin degludec.
An overall flat PK/PD profile and an evenly distributed exposure over 24 hours were observed for Toujeo(R) at both dose levels studied (0.4 and 0.6 U/kg/day).
"These new findings may have clinical implications for people with type 1 diabetes on basal insulin therapy," said Dr. Timothy Bailey, Clinical Associate Professor, University of California, San Diego. "Toujeo(R) has already shown an improved PK/PD profile when compared to insulin glargine 100 Units/mL (Gla-100), with a flatter profile. Also in a previous CGM study in adults with type 1 diabetes versus Gla-100, Toujeo showed less between-day variability and less within-day fluctuations, associated with a lower risk of nocturnal confirmed (less than or equal to54 mg/dL) or severe hypoglycemia in the first 8 weeks. The results observed in the current PK/PD study comparing Toujeo(R) versus Deg-100 confirm that Toujeo has an interesting profile with the potential to help the people with diabetes to reach their targets with less risk of hypoglycemia."
"In this PK/PD study, we observed a more favorable profile for Toujeo(R) compared to insulin degludec," said Riccardo Perfetti, Head of Global Diabetes Medical Team, Sanofi. "The clinical implications of these findings are currently being investigated."
About Toujeo(R) PK/PD study (LPS14585)
Although basal insulin injections cannot perfectly replicate endogenous insulin production, the 'ideal' basal insulin for diabetes therapy would have stable pharmacodynamic (PD) and pharmacokinetic (PK) profiles. Smaller and less variable glucose excursions may result in more predictable 24hour profiles and less hypoglycemia, and could translate into an improved experience for people on basal insulin and better adherence to therapy.
This was a randomized, double-blind, 2x2, crossover, euglycemic-clamp study in two parallel cohorts of people with type 1 diabetes (48 people in total) to compare the pharmacodynamic and pharmacokinetic properties of 0.4 and 0.6 U/kg/day insulin glargine 300 Units/mL (Toujeo(R), Gla-300) with the same dose levels of insulin degludec 100 Units/mL (Deg-100) in steady state after 8 days multiple dosing regimen.
Within-day fluctuation of the smoothed glucose infusion rate (GIR-smFL0-24) was significantly lower with Gla-300 versus Deg-100 at the 0.4 U/kg dose level. At the 0.4 U/kg dose level, relative 6-hour fractions of GIR-AUC0-24 were more evenly distributed with Gla-300 versus Deg-100. GIR-smFL0-24 and 6-hour fractions of GIR-AUC0-24 were similar between insulins at the supra-therapeutic 0.6 U/kg dose level. At both dose levels, GIR-AUC0-24 and GIRmax were lower for Gla-300 versus Deg-100, while T50%-GIR-AUC0-24 and duration of BG control were similar foreach insulin.
Both dose levels of Gla-300 provided plateau-like insulin profiles up to 16 hours post-dose, followed by a subsequent slow decline. For Deg-100, insulin increased at both dose levels from the time of injection until ~10 hours after dosing, with subsequent slow decline. Exposure of both insulins was measurable until clamp end (30 hours). At both dose levels the 6-hour fractions of INS-AUC0-24 were more evenly distributed with Gla-300 versus Deg-100.
About Toujeo(R) CGM study
Continuous glucose monitoring (CGM), is a valuable way to confirm whether the differences observed in the PK and PD properties of insulins under experimental condition translate to clinically relevant differences in their 24-hour glucose profiles and other parameters of glycemic control, including hypoglycemia.
This was a multicenter, 16-week, open-label, Phase II, parallel-group, two-period crossover study including 59 people with type 1 diabetes (PDY12777; NCT01658579). The primary endpoint was the mean percentage of time within the glucose range of 4.4-7.8 mmol/L (80-140 mg/dL) during the last 2 weeks of treatment in each treatment period (Weeks 7-8 and Weeks 15-16). The main secondary endpoints were the average 24-hour glucose profiles based on CGM (mmol/L) for the last 2 weeks of treatment in each treatment period and the incidence of participants experiencing at least one hypoglycemic event (defined by American Diabetes Association criteria) in either study period.
The percentage of time within the glucose range of 4.4-7.8 mmol/L (primary endpoint) was similar for participants receiving Gla-300 vs Gla-100 (LS mean difference 0.75%, p=0.73). Average 24-hour glucose profiles showed a more constant glucose level with Gla-300 vs. Gla-100.
Toujeo(R) is a once-daily basal insulin based on a broadly-used molecule (insulin glargine). Toujeo has been approved by the U.S. Food and Drug Administration (FDA), the European Commission, Health Canada, the Therapeutic Goods Administration in Australia, and the MHLW in Japan (where its approved brand name is Lantus(R) XR), and is under review by other regulatory authorities around the world.
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial.
1) Bailey T, et al. Insulin Glargine 300 U/mL (Gla-300) Provides More Stable and More
Evenly Distributed Steady-state PK/PD Profiles Compared with Insulin Degludec in Type
1 Diabetes. Poster presented at Diabetes Technology Meeting, November 11, 2016
2) Data on file, Adelphi Real World Diabetes DSP XII, 2015.
3) Bergenstal RM, et al. Diabetes Technol Ther 2015;17(S1):16 (Abstract 39)
CONTACT: Global Diabetes Communications, Serge Spierckel,+33(0)6-75-71-61-24, email@example.com; Investor Relations, GeorgeGrofik, +33(0)1-53-77-45-45, firstname.lastname@example.org;Corporate Communications, Mai Tran, +33(0)1-53-77-49-86,email@example.com